Compare SQNS & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SQNS | SCLX |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.3M | 90.0M |
| IPO Year | 2011 | N/A |
| Metric | SQNS | SCLX |
|---|---|---|
| Price | $5.32 | $10.98 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $21.33 | N/A |
| AVG Volume (30 Days) | ★ 206.8K | 77.5K |
| Earning Date | 02-10-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $31,534,000.00 | ★ $40,360,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.61 | $749.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.20 | N/A |
| 52 Week Low | $4.44 | $3.60 |
| 52 Week High | $58.30 | $34.27 |
| Indicator | SQNS | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 49.60 | 35.63 |
| Support Level | $5.13 | $10.35 |
| Resistance Level | $5.50 | $13.83 |
| Average True Range (ATR) | 0.27 | 0.94 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 48.55 | 25.24 |
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.